{"id":26812,"date":"2020-07-17T13:08:51","date_gmt":"2020-07-17T13:08:51","guid":{"rendered":"https:\/\/www.ceo-na.com\/?p=26812"},"modified":"2020-07-17T18:08:56","modified_gmt":"2020-07-17T18:08:56","slug":"clinical-leaders-top-concerns-about-reopening","status":"publish","type":"post","link":"http:\/\/servidor-mxigen1.com\/ceona-antiguo\/business\/industry\/clinical-leaders-top-concerns-about-reopening\/","title":{"rendered":"Clinical leaders’ top concerns about reopening"},"content":{"rendered":"

Deloitte explores the resources\u00a0health care organization need and the possible timelines for pre-COVID-19 levels.<\/p>\n

<\/p>\n

Article by<\/strong>\u00a0David Betts<\/a>,\u00a0Doug Billings<\/a>,\u00a0Natasha Elsner<\/a>,\u00a0Hemnabh Varia<\/a> |<\/strong> Deloitte<\/a><\/p>\n

The\u00a0COVID-19 pandemic forced many health care providers to stop performing nonurgent procedures in response to state mandates, to ensure the safety of patients and staff, and to deploy resources toward COVID-19 treatment. Much lower volumes of these procedures have led to a considerable drop in revenue. As COVID-19 cases recede, how are hospitals and health systems going about resuming these procedures?<\/p>\n

In May 2020, the Deloitte Center for Health Solutions surveyed clinical leaders to understand their concerns, approaches, and steps toward resuming nonurgent procedures.<\/p>\n

Key Findings<\/h1>\n

The results suggest that resuming nonurgent procedures will be complex, and clinical leaders are preparing for many uncertainties.<\/p>\n

Top concerns include a potential second outbreak, low patient demand, and supplies<\/h3>\n

While health systems have been at the frontline of caring for patients during the epidemic and have received some financial support from federal legislation, the loss of revenue has been a significant financial challenge for many. Surveyed clinical leaders estimate that the nonurgent procedure volume in April 2020 was just 16% of what it was during the same period last year.<\/p>\n

When asked to list their top three concerns about resuming deferred procedures, clinical leaders cite the possibility of an outbreak or a second wave as their number one worry (82%), overshadowing all other concerns. Low patient demand due to safety concerns (54%) and adequate supply of materials, medications, equipment or testing (50%) are a distant second, followed by patients\u2019 ability to pay due to loss of income or insurance (40%).<\/p>\n

\n
\"\"<\/div>\n
<\/div>\n<\/div>\n
When it comes to supply chain, the top three concerns include testing capabilities (74%), personal protective equipment or PPE (68%), and the availability of medical and surgical supplies other than PPE (58%). These are all areas in which suppliers can support their customers.<\/div>\n
<\/div>\n
\"\"<\/div>\n
<\/div>\n
\n

Organizations probably have the least control over the possibility of another outbreak or wave. And a large outbreak can have cascading effects on other important variables: patient demand, availability of testing and supplies, and staffing.<\/p>\n

Lingering supply chain issues and the possibility of new outbreaks should compel organizations to rethink how they stock, distribute, forecast, and track supplies by site and service line. Providers may have a newfound desire for upstream visibility into the supply chain, whereas suppliers might want a detailed understanding of downstream utilization. This would call for a much closer coordination among supply chain stakeholders: providers, group purchasing organizations (GPOs), distributors, and medtech companies.<\/p>\n

Adequate testing is the key capability organizations are looking for<\/h3>\n

In response to our question about what capabilities are still lacking, sufficient testing (for the virus and for antibodies) tops the list (figure 3).<\/p>\n

While both clinical leaders at organization\/system level and leaders at the service line level agree about the lack of testing, their perspectives diverge on three other capabilities:<\/p>\n